Ulipristal is a progesterone agonist/antagonist indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure. It is available as tablets for oral use. MedsAcross supplies Ulipristal for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Ella is a progesterone agonist/antagonist emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure. Ella is not intended for routine use as a contraceptive.
Source: US FDA prescribing information
When taken immediately before ovulation is to occur, ella postpones follicular rupture. The likely primary mechanism of action of ulipristal acetate for emergency contraception is therefore inhibition or delay of ovulation, however, alterations to the endometrium that may affect implantation may also contribute to efficacy.
Source: US FDA prescribing information
• Take one tablet orally as soon as possible, within 120 hours (5 days) after unprotected intercourse or a known or suspected contraceptive failure. Take with or without food. Take at any time during the menstrual cycle. • After ella use, initiate or resume hormonal contraception no sooner than 5 days after the intake of ella and use a reliable barrier method until the next menstrual period. • If vomiting occurs within 3 hours of taking ella, consider repeating the dose.
Source: US FDA prescribing information
Ella is contraindicated for use in the case of known or suspected pregnancy. • Known or suspected pregnancy
Source: US FDA prescribing information
• Existing Pregnancy: ella is not indicated for termination of an existing pregnancy. • Ectopic pregnancy: Evaluate women who become pregnant or complain of lower abdominal pain after taking ella for ectopic pregnancy. • Fertility Following Use: Rapid return of fertility is likely. Subsequent acts of intercourse should be protected by a reliable barrier method of contraception until the next menstrual period. • Effect on Menstrual Cycle: ella may alter the next expected menses. If menses is delayed beyond 1 week, rule out pregnancy. • Ella does not protect against STI/HIV.
Source: US FDA prescribing information
The most common adverse reactions (≥ 5%) in the clinical trials were headache (18%), abdominal pain (12%), nausea (12%), dysmenorrhea (9%), fatigue (6%) and dizziness (5%).
Source: US FDA prescribing information
Several in vivo drug interaction studies have shown that ella is predominantly metabolized by CYP3A4. • Drugs or herbal products that induce CYP3A4 decrease the effectiveness of ella. • Initiation of progestin-containing contraceptives may impair the ability of ella to delay ovulation.
Source: US FDA prescribing information
Store at 20-25°C (68-77°F), excursions permitted to 15-30°C (59-86°F) Keep the blister in the outer carton in order to protect from light.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Ulipristal, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Ella 30 mg tabletOral | PMI Branded Pharmaceuticals | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Yes, on request. MedsAcross lists 1 presentations of Ulipristal and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Ulipristal, including Ella.
Yes. The US FDA first approved Ulipristal on 13 August 2010, according to Drugs@FDA.
Yes. Ulipristal has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Ulipristal is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Ulipristal is classified under ATC code G03AD02 (Ulipristal).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.